Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Aciclovir

Drug and asset intelligence for Aciclovir with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
3
Stage
Development stage unavailable

Sponsor company

Aurobindo Pharma →

Recent signals(3)

StrategyJuly 12, 2026

FDA Grants Approval for Aciclovir ANDA215669 by Hetero Labs

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 215669 for aciclovir submitted by Hetero Labs.

StrategyJuly 9, 2026

Aurobindo Pharma's Aciclovir ANDA216331 Receives AP Status from FDA

Aurobindo Pharma's Abbreviated New Drug Application (ANDA) for Aciclovir has received an Approved Pending (AP) status from the FDA.

RegulatoryJune 30, 2026

Aurobindo Pharma's Aciclovir Supplement Application Receives Standard Review Status

Aurobindo Pharma USA has submitted a supplement application for Aciclovir (ANDA075211) which is currently under standard review by the FDA.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

Hetero Labs — Aciclovir

July 12, 2026 · N/A

Topline Data

Aurobindo Pharma — Aciclovir

July 9, 2026 · N/A

Topline Data

Aurobindo Pharma — Aciclovir

June 30, 2026 · N/A

Indications

Infectious Disease →

Therapeutic areas

Antiviral →
Infectious Disease →
Infectious Disease · Antiviral →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.